Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E.. Endocr. Relat. Cancer. 2015; 289-98: p.289-98Article
Oncostat